

Attorney Docket No.: RTSP-0155
Inventors: Monia and Cowser
Serial No.: 09/913,800
Filing Date: March 1, 2002
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): An antisense compound 8 to 30 nucleotides in length ~~targeted to a nucleic acid molecule encoding human Akt 2, wherein said antisense compound inhibits the expression of human Akt 2~~ comprising at least an 8-nucleobase portion of SEQ ID NO: 32 or 21.

Claim 2 (original): The antisense compound of claim 1 which is an antisense oligonucleotide.

Claims 3-4 (canceled).

Claim 5 (original): The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 6 (original): The antisense compound of claim 5 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 7 (original): The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Attorney Docket No.: RTSP-0155
Inventors: Monia and Cowser
Serial No.: 09/913,800
Filing Date: March 1, 2002
Page 3

Claim 8 (original): The antisense compound of claim 7 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Claim 9 (original): The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 10 (original): The antisense compound of claim 9 wherein the modified nucleobase is a 5-methylcytosine.

Claim 11 (original): The antisense compound of claim 1 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 12 (original): A pharmaceutical composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The pharmaceutical composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original): The pharmaceutical composition of claim 12 wherein the antisense compound is an antisense oligonucleotide.

Claim 15 (original): A method of inhibiting the expression of Akt-2 in human cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of Akt-2 is inhibited.

Attorney Docket No.: RTSP-0155
Inventors: Monia and Cowser
Serial No.: 09/913,800
Filing Date: March 1, 2002
Page 4

Claim 16 (original): A method of treating a human having a disease or condition associated with Akt-2 comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of Akt-2 is inhibited.

Claim 17 (original): The method of claim 16 wherein the disease or condition is a hyperproliferative disorder.

Claim 18 (original): The method of claim 17 wherein the hyperproliferative disorder is cancer.